CA2491310A1 - Compositions comprising cell-impermeant duramycin derivatives - Google Patents
Compositions comprising cell-impermeant duramycin derivatives Download PDFInfo
- Publication number
- CA2491310A1 CA2491310A1 CA002491310A CA2491310A CA2491310A1 CA 2491310 A1 CA2491310 A1 CA 2491310A1 CA 002491310 A CA002491310 A CA 002491310A CA 2491310 A CA2491310 A CA 2491310A CA 2491310 A1 CA2491310 A1 CA 2491310A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- antibody
- agent
- operatively attached
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
Claims (93)
1. A composition comprising a purified antibody, or antigen-binding fragment or immunoconjugate thereof, wherein said antibody binds to phosphatidylserine and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to phosphatidylserine.
2. The composition of claim 1, wherein said antibody further binds to phosphatidic acid and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to phosphatidic acid.
3. The composition of claim 1, wherein said antibody further binds to phosphatidylinositol and effectively competes with the monoclonal antibody 3G4 (ATCC PTA
4545) for binding to phosphatidylinositol.
4545) for binding to phosphatidylinositol.
4. The composition of claim 1, wherein said antibody further binds to phosphatidylglycerol and effectively competes with the monoclonal antibody 3G4 (ATCC
PTA 4545) for binding to phosphatidylglycerol.
PTA 4545) for binding to phosphatidylglycerol.
5. The composition of claim 1, wherein said antibody further binds to cardiolipin and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to cardiolipin.
6. The composition of claim 1, wherein said antibody further binds to phosphatidic acid, phosphatidylinositol, phosphatidylglycerol and cardiolipin and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to each of phosphatidic acid, phosphatidylinositol, phosphatidylglycerol and cardiolipin.
7. The composition of claim 1, wherein said antibody further binds to phosphatidylethanolamine.
8. The composition of claim 7, wherein said antibody further binds to phosphatidylethanolamine and effectively competes with the monoclonal antibody (ATCC PTA 4545) for binding to phosphatidylethanolamine.
9. The composition of claim 1, wherein said antibody has substantially the same phospholipid binding profile as the monoclonal antibody 3G4 (ATCC PTA 4545) as set forth in Table 4.
10. The composition of claim 1, wherein said antibody has an affinity for phosphatidylserine of at least equal to the affinity of the monoclonal antibody 3G4 (ATCC
PTA 4545) for phosphatidylserine as set forth in Table 3.
PTA 4545) for phosphatidylserine as set forth in Table 3.
11. The composition of claim 1, wherein said antibody has substantially the same phospholipid binding profile as the monoclonal antibody 3G4 (ATCC PTA 4545), as set forth in Table 4, and has an affinity for phosphatidylserine of at least equal to the affinity of the monoclonal antibody 3G4 (ATCC PTA 4545) for phosphatidylserine, as set forth in Table 3.
12. The composition of claim 1, wherein said antibody is a monoclonal antibody.
13. The composition of claim 1, wherein said antibody is an IgG antibody.
14. The composition of claim 1, wherein said antibody is an antigen-binding fragment of an antibody.
15. The composition of claim 14, wherein said antibody is an scFv, Fv, Fab', Fab, diabody, linear antibody or F(ab')2 antigen-binding fragment of an antibody.
16. The composition of claim 14, wherein said antibody is a CDR, univalent fragment, camelized or single domain antibody.
17. The composition of claim1, wherein said antibody is a human, humanized or part-human antibody or antigen-binding fragment thereof.
18. The composition of claim 17, wherein said antibody comprises an antigen-binding region of said antibody operatively attached to a human antibody framework or constant region.
19. The composition of claim 1, wherein said antibody is a chimeric antibody.
20. The composition of claim 1, wherein said antibody is a bispecific antibody.
21. The composition of claim 1, wherein said antibody is a recombinant antibody.
22. The composition of claim 1, wherein said antibody is an engineered antibody.
23. The composition of claim 1, wherein said antibody is prepared by a process comprising immunizing an animal with activated endothelial cells and selecting from the immunized animal an antibody that binds to phosphatidylserine and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to phosphatidylserine.
24. The composition of claim 1, wherein said antibody comprises at least a first variable region that includes an amino acid sequence region having the amino acid sequence of SEQ ID
NO:2 or SEQ ID NO:4.
NO:2 or SEQ ID NO:4.
25. The composition of claim 1, wherein said antibody is the monoclonal antibody 3G4 (ATCC PTA 4545).
26. The composition of any one of claims ~ through 25, wherein said antibody is operatively attached to at least a first biological agent.
27. The composition of claim 26, wherein said antibody is operatively attached to at least a first agent that cleaves a substantially inactive prodrug to release a substantially active drug.
28. The composition of claim 27, wherein said antibody is operatively attached to arylsulfatase, serratia protease, thermolysin, subtilisin, a carboxypeptidase, a cathepsin, D-alanylcarboxypeptidase, .beta.-galactosidase, neuraminidase, .beta.-lactamase, penicillin amidase or cytosine deaminase that cleaves a substantially inactive prodrug to release a substantially active drug.
29. The composition of claim 27, wherein said antibody is operatively attached to alkaline phosphatase that cleaves a substantially inactive phosphate-prodrug to release a substantially active drug.
30. The composition of claim 26, wherein said antibody is operatively attached to at least a first therapeutic or diagnostic agent.
31. The composition of claim 30, wherein said antibody is operatively attached to at least a first therapeutic agent.
32. The composition of claim 31, wherein said antibody is operatively attached to at least a first chemotherapeutic agent, radiotherapeutic agent, anti-angiogenic agent, apoptosis-inducing agent, steroid, antimetabolite, anthracycline, vinca alkaloid, anti-tubulin drug, antibiotic, cytokine, alkylating agent or coagulant.
33. The composition of claim 32, wherein said antibody is operatively attached to TNF.alpha., IL-12 or LEC.
34. The composition of claim 32, wherein said antibody is operatively attached to a cytotoxic, cytostatic or anticellular agent capable of killing or suppressing the growth or cell division of endothelial cells.
35. The composition of claim 34, wherein said antibody is operatively attached to a plant-, fungus- or bacteria-derived toxin.
36. The composition of claim 35, wherein said antibody is operatively attached to an A chain toxin, a ribosome inactivating protein, .alpha.-sarcin, gelonin, aspergillin, restrictocin, a ribonuclease, an epipodophyllotoxin, diphtheria toxin or Pseudomonas exotoxin.
37. The composition of claim 36, wherein said antibody is operatively attached to ricin A
chain or deglycosylated ricin A chain.
chain or deglycosylated ricin A chain.
38. The composition of claim 32, wherein said antibody is operatively attached to an anti-angiogenic agent.
39. The composition of claim 32, wherein said antibody is operatively attached to an anti-tubulin drug.
40. The composition of claim 39, wherein said antibody is operatively attached to an anti-tubulin drug selected from the group consisting of colchicine, taxol, vinblastine, vincristine, vindescine and a combretastatin.
41. The composition of claim 32, wherein said antibody is operatively attached to a coagulant.
42. The composition of claim 30, wherein said antibody is operatively attached to a diagnostic, imaging or detectable agent.
43. The composition of claim 42, wherein said antibody is operatively attached to an X-ray detectable compound, a radioactive ion or a nuclear magnetic spin-resonance isotope.
44. The composition of claim 43, wherein said antibody is operatively attached to:
(a) the X-ray detectable compound bismuth (III), gold (III), lanthanum (III) or lead (II);
(b) the detectable radioactive ion copper67, gallium67, gallium68, indium111, indium113, iodine123, iodine125, iodine131, mercury197, mercury203, rhenium186, rhenium188, rubidium97, rubidium103, technetium99m or yttrium90; or (c) the detectable nuclear magnetic spin-resonance isotope cobalt (II), copper (II), chromium (III), dysprosium (III), erbium (III), gadolinium (III), holmium (III), iron (II), iron (III), manganese (II), neodymium (III), nickel (II), samarium (III), terbium (III), vanadium (II) or ytterbium (III).
(a) the X-ray detectable compound bismuth (III), gold (III), lanthanum (III) or lead (II);
(b) the detectable radioactive ion copper67, gallium67, gallium68, indium111, indium113, iodine123, iodine125, iodine131, mercury197, mercury203, rhenium186, rhenium188, rubidium97, rubidium103, technetium99m or yttrium90; or (c) the detectable nuclear magnetic spin-resonance isotope cobalt (II), copper (II), chromium (III), dysprosium (III), erbium (III), gadolinium (III), holmium (III), iron (II), iron (III), manganese (II), neodymium (III), nickel (II), samarium (III), terbium (III), vanadium (II) or ytterbium (III).
45. The composition of claim 42, wherein said antibody is operatively attached to biotin, avidin or to an enzyme that generates a colored product upon contact with a chromogenic substrate.
46. The composition of claim 31, wherein said antibody is operatively attached to at least a first anti-viral agent.
47. The composition of claim 46, wherein said antibody is operatively attached to an anti-viral agent from Table G.
48. The composition of claim 46, wherein said antibody is operatively attached to cidofovir or AZT.
49. The composition of claim 26, wherein said antibody is operatively attached to said biological agent as a fusion protein prepared by expressing a recombinant vector that comprises, in the same reading frame, a DNA segment encoding said antibody operatively linked to a DNA segment encoding said biological agent.
50. The composition of claim 26, wherein said antibody is operatively attached to said biological agent via a biologically releasable bond or selectively cleavable linker.
51. The composition of claim ~, wherein said composition is a pharmaceutically acceptable composition that further comprises a pharmaceutically acceptable carrier.
52. The composition of claim 51, wherein said pharmaceutically acceptable composition is formulated for parenteral administration.
53. The composition of claim 51, wherein said pharmaceutically acceptable composition is a liposomal formulation.
54. The composition of claim 53, wherein said pharmaceutically acceptable composition is a stealthed or PEGylated liposomal formulation.
55. The composition of claim 53, wherein said pharmaceutically acceptable composition is a stealthed or PEGylated liposomal formulation that is coated with said antibody.
56. The composition of claim ~, wherein said composition further comprises a second biological agent.
57. The composition of claim 56, wherein said composition further comprises a second therapeutic agent.
58. The composition of claim 57, wherein said second therapeutic agent is an anti-angiogenic agent.
59. The composition of claim 57, wherein said second therapeutic agent is an anti-cancer agent.
60. The composition of claim 59, wherein said anti-cancer agent is a compound that interferes with DNA replication, mitosis or chromosomal segregation.
61. The composition of claim 59, wherein said anti-cancer agent is a chemotherapeutic agent, radiotherapeutic agent, anti-angiogenic agent, apoptosis-inducing agent, anti-tubulin drug or a tumor-targeted chemotherapeutic agent, radiotherapeutic agent, anti-angiogenic agent, apoptosis-inducing agent or anti-tubulin drug.
62. The composition of claim 61, wherein said anti-cancer agent is cytosine arabinoside, methotrexate, aminopterin, demecolcine, mithramycin, chlorambucil, melphalan, daunorubicin, doxorubicin, verapamil, tamoxifen, taxol, vincristine, vinblastine, etoposide, 5-fluorouracil (5FU), camptothecin, actinomycin-D, mitomycin C, cisplatin, bleomycin, a combretastatin or cyclophosphamide.
63. The composition of claim 61, wherein said anti-cancer agent is docetaxel.
64. The composition of claim 61, wherein said anti-cancer agent is an anti-tubulin drug, a tumor-targeted anti-tubulin drug or a compound that interferes with tubulin activity.
65. The composition of claim 61, wherein said anti-cancer agent is a targeting agent-therapeutic agent construct comprising a therapeutic agent operatively linked to a targeting region that binds to an accessible component of a tumor cell or tumor stroma or to a surface-expressed, surface-accessible, surface-localized, cytokine-inducible or coagulant-inducible component of tumor vasculature or intratumoral vasculature.
66. The composition of claim 59, wherein said anti-cancer agent is dispersed within a liposomal formulation.
67. The composition of claim 59, wherein said anti-cancer agent is dispersed within a stealthed or PEGylated liposomal formulation that is coated with said antibody.
68. The composition of claim 57, wherein said second therapeutic agent is an anti-viral agent.
69. The composition of claim 68, wherein said anti-viral agent is an anti-viral agent selected from Table G.
70. The composition of claim 68, wherein said anti-viral agent is cidofovir or AZT.
71. A composition comprising a substantially cell impermeant duramycin derivative, comprising a duramycin peptide operatively attached to a cell impermeant group.
72. The composition of claim 71, wherein said duramycin peptide is operatively attached to a group that bears a positive charge at physiological pH.
73. The composition of claim 71, wherein said duramycin peptide is operatively attached to a group that bears a negative charge at physiological pH.
74. The composition of claim 71, wherein said duramycin peptide is operatively attached to biotin, or to a sulfate, sulfonate, phosphate, carboxyl, phenolic, quaternary ammonium ion or amine group.
75. The composition of claim 71, wherein said duramycin peptide is operatively attached to a sugar, oligo- or polysaccharide, amino acid, peptide, polypeptide or a polyalcohol group.
76. The composition of claim 71, wherein said duramycin peptide is operatively attached to a protein.
77. The composition of claim 71, wherein said duramycin peptide is operatively attached to an inert carrier protein.
78. The composition of claim 71, wherein duramycin peptide is operatively attached to neutravidin, streptavidin, albumin or an inert immunoglobulin carrier protein.
79. The composition of claim 71, wherein said duramycin peptide is operatively attached to a targeting protein, antibody, or antigen binding region thereof, that binds to a tumor cell, tumor vasculature or tumor stroma.
80. The composition of claim 71, said substantially cell impermeant duramycin derivative is a substantially cell impermeant duramycin derivative as set forth in any one of FIG. 13A
through FIG. 13O.
through FIG. 13O.
81. A composition comprising a duramycin peptide operatively attached to at least a first anti-viral agent.
82. The composition of claim 81, wherein said duramycin peptide is operatively attached to at least a first anti-viral agent selected from Table G.
83. The composition of claim 81, wherein said duramycin peptide is operatively attached to cidofovir or AZT.
84. The composition of any preceding claim, for use in therapy.
85. The composition of any preceding claim, for use in inhibiting angiogenesis.
86. The composition of any preceding claim, for use in treating cancer.
87. The composition of any preceding claim, for use in treating a viral infection.
88. Use of a composition in accordance with any preceding claim in the manufacture of a medicament for treating a disease by inhibiting angiogenesis.
89. Use of a composition in accordance with any preceding claim in the manufacture of a medicament for treating macular degeneration, age-related macular degeneration, arthritis, rheumatoid arthritis, atherosclerosis, diabetic retinopathy, thyroid hyperplasia, Grave's disease, hemangioma, neovascular glaucoma or psoriasis.
90. Use of a composition in accordance with any preceding claim in the manufacture of a medicament for treating cancer.
91. Use of a composition in accordance with any preceding claim in the manufacture of a medicament for treating a viral infection.
92. Use of a composition in accordance with any preceding claim in the manufacture of a medicament for treating a viral disease as set forth in Table J.
93. Use of a composition in accordance with any preceding claim in the manufacture of a medicament for treating a CMV, RSV, or arenavirus infection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2894009A CA2894009C (en) | 2002-07-15 | 2003-07-15 | Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39626302P | 2002-07-15 | 2002-07-15 | |
US60/396,263 | 2002-07-15 | ||
PCT/US2003/021925 WO2004006847A2 (en) | 2002-07-15 | 2003-07-15 | Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2894009A Division CA2894009C (en) | 2002-07-15 | 2003-07-15 | Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2491310A1 true CA2491310A1 (en) | 2004-01-22 |
CA2491310C CA2491310C (en) | 2015-10-06 |
Family
ID=30115998
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2491310A Expired - Fee Related CA2491310C (en) | 2002-07-15 | 2003-07-15 | Compositions comprising cell-impermeant duramycin derivatives |
CA2894009A Expired - Lifetime CA2894009C (en) | 2002-07-15 | 2003-07-15 | Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2894009A Expired - Lifetime CA2894009C (en) | 2002-07-15 | 2003-07-15 | Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment |
Country Status (20)
Country | Link |
---|---|
US (2) | US20040175378A1 (en) |
EP (8) | EP2263697A3 (en) |
JP (7) | JP4827411B2 (en) |
KR (8) | KR101690826B1 (en) |
CN (5) | CN101653603B (en) |
AT (1) | ATE491725T1 (en) |
AU (2) | AU2003247869C1 (en) |
BR (1) | BR0312692A (en) |
CA (2) | CA2491310C (en) |
DE (1) | DE60335383D1 (en) |
DK (3) | DK2269656T3 (en) |
ES (2) | ES2358730T3 (en) |
HK (5) | HK1075256A1 (en) |
IL (5) | IL165267A0 (en) |
MX (2) | MXPA05000652A (en) |
NZ (5) | NZ537690A (en) |
PT (2) | PT1537146E (en) |
SI (1) | SI2269656T1 (en) |
WO (1) | WO2004006847A2 (en) |
ZA (1) | ZA200500363B (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645739B2 (en) * | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
US7714109B2 (en) * | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
US7615223B2 (en) * | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
US7622118B2 (en) * | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
US7247303B2 (en) * | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
BR0312692A (en) * | 2002-07-15 | 2007-06-26 | Univ Texas | selected antibodies and duramycin peptides that bind to anionic phospholipids and aminophospholipids and their uses in the treatment of viral infections and cancer |
US7625563B2 (en) * | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
US7678386B2 (en) * | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
US7378386B2 (en) | 2002-07-15 | 2008-05-27 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives |
US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
US20110002978A1 (en) * | 2003-06-17 | 2011-01-06 | Harrison Roger G | Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof |
WO2006055855A2 (en) * | 2004-11-19 | 2006-05-26 | Mcw Research Foundation, Inc. | Method of imaging cell death in vivo |
AU2006206187B2 (en) * | 2005-01-24 | 2011-03-10 | Board Of Regents, The University Of Texas System | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use |
WO2006110831A2 (en) | 2005-04-12 | 2006-10-19 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
WO2006114115A1 (en) | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Combination of antibodies and glucocorticoids for treating cancer |
JP2009520793A (en) * | 2005-12-22 | 2009-05-28 | ドマンティス リミテッド | Composition |
US20110014270A1 (en) * | 2006-03-27 | 2011-01-20 | The Regents Of The University Of Colorado | Prevention and treatment of ischemia-reperfusion injury and related conditions |
US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
US8796429B2 (en) | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
US20080138334A1 (en) | 2006-05-31 | 2008-06-12 | Sabbadini Roger A | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same |
AU2008232677B2 (en) | 2007-03-29 | 2013-09-19 | National Jewish Health | Surfactant lipids, compositions thereof, and uses thereof |
CA2683752A1 (en) | 2007-04-13 | 2008-10-23 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
US8501792B2 (en) | 2008-02-19 | 2013-08-06 | David A. Potter | Treating cancer with desthiazolyl ritonavir |
AU2009223677A1 (en) * | 2008-03-10 | 2009-09-17 | Mcw Research Foundation, Inc. | 99mTc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical |
CN102062718B (en) * | 2009-11-17 | 2012-11-21 | 国家纳米科学中心 | Method for measuring relative absorption constants of dye, antibody, medicament and medicament prosoma molecules on polypeptide molecules |
WO2011103531A1 (en) * | 2010-02-21 | 2011-08-25 | Bayer Healthcare Llc | Method for Activation and Conjugation of Biomolecules |
CN102614536B (en) * | 2012-03-31 | 2013-01-30 | 南京市第一医院 | Cell apoptosis imaging medicament 68Ga-NOTA-Duramycin and preparation method thereof |
BR112015025347A2 (en) | 2013-04-09 | 2017-07-18 | Boston Biomedical Inc | 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment |
US10035009B2 (en) | 2013-04-15 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treating pancreatic cancer |
US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
WO2015092035A1 (en) * | 2013-12-20 | 2015-06-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cd300a receptors as virus entry cofactors |
US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
US20170363612A1 (en) * | 2014-12-03 | 2017-12-21 | Wayne State University | Compositions and methods relating to proliferative disorders |
WO2016167798A1 (en) * | 2015-04-17 | 2016-10-20 | Northwestern University | Phosphatidylethanolamine-specific probes |
TW201717935A (en) | 2015-06-03 | 2017-06-01 | 波士頓生醫公司 | Compositions and methods for treating cancer |
CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
CN110914300A (en) * | 2017-04-03 | 2020-03-24 | 安康乐济股份有限公司 | Methods of treating cancer using PS-targeted antibodies and immunooncology agents |
JP2020520923A (en) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル, インコーポレイテッド | Methods for treating cancer |
WO2018220224A1 (en) * | 2017-06-02 | 2018-12-06 | Medirista Biotechnologies Ab | Lipid-related antigens and antibodies directed against them |
WO2020032951A1 (en) | 2018-08-09 | 2020-02-13 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
US11591718B2 (en) | 2018-04-27 | 2023-02-28 | Aimed Bio Inc. | Magnetic-based biopanning method through attachment of magnetic bead to cell |
JP7397874B2 (en) * | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Multichain chimeric polypeptides and their uses |
JP2023526880A (en) * | 2020-05-26 | 2023-06-26 | ウニヴェルシテーツメディツィン・デア・ヨハネス・グーテンベルク-ウニヴェルシテート・マインツ | Methods and compositions for treating coronavirus infections and related clotting disorders |
KR102400464B1 (en) | 2020-07-28 | 2022-05-19 | 부산대학교 산학협력단 | Biomarker composition for detecting cancer stem cell |
Family Cites Families (195)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US399A (en) | 1837-09-22 | Slide-valve for steam-engines | ||
US6093A (en) | 1849-02-06 | Horatio allen | ||
US652458A (en) | 1899-08-12 | 1900-06-26 | Josephine A Fayart | Apparel-waist. |
GB880421A (en) | 1957-08-02 | 1961-10-18 | Roussel Uclaf | Improvements in or relating to the production of esters of bis-(carboxymethylthio)-methane |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US5583013A (en) | 1977-11-08 | 1996-12-10 | Genentech, Inc. | Method and means for microbial polypeptide expression |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4366246A (en) | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
US5221619A (en) | 1977-11-08 | 1993-06-22 | Genentech, Inc. | Method and means for microbial polypeptide expression |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
CA1172980A (en) | 1979-04-02 | 1984-08-21 | Kenji Takemoto | Pentadecapeptide and process for the preparation thereof |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4505899A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4436728A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4435386A (en) | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4505900A (en) | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
JPS5942322A (en) * | 1982-09-01 | 1984-03-08 | Meiji Milk Prod Co Ltd | Carcinostatic agent |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
JPH076984B2 (en) * | 1985-05-31 | 1995-01-30 | 株式会社日立製作所 | Multiple item analysis method |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4785420A (en) | 1986-04-09 | 1988-11-15 | Joyce Communications Systems, Inc. | Audio/telephone communication system for verbally handicapped |
US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US4996237A (en) | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
CA1338645C (en) | 1987-01-06 | 1996-10-15 | George R. Pettit | Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins" |
US5834599A (en) * | 1987-05-29 | 1998-11-10 | Tanox Biosystems, Inc. | Immunoconjugates which neutralize HIV-1 infection |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
US5520914A (en) | 1987-08-06 | 1996-05-28 | President And Fellows Of Harvard College | Antibodies to angiogenin: immunotherapeutic agents |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
US5183756A (en) | 1988-08-19 | 1993-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4940726A (en) | 1989-04-26 | 1990-07-10 | Arizona Board Of Regents | Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2 |
CA2018273C (en) | 1989-06-09 | 1999-04-06 | Peter D. Senter | Thermally stable cytosine deaminase |
US5338678A (en) | 1989-06-09 | 1994-08-16 | Oncogen, A Limited Partnership | Expression of DNA sequences encoding a thermally stable cytosine deaminase from saccharomyces |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5270196A (en) | 1989-10-20 | 1993-12-14 | Bristol-Myers Squibb Company | Arylsulfatase from streptomyces |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE3938140A1 (en) * | 1989-11-16 | 1991-08-08 | Beiersdorf Ag | DESODRATING COSMETIC AGENTS |
US5627036A (en) | 1989-12-27 | 1997-05-06 | Boehringer Ingelheim International Gmbh | Use of an anticoagulant as a diagnostic agent |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5972922A (en) | 1990-06-11 | 1999-10-26 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (en) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Process for producing specific binding pair elements |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5242813A (en) | 1990-10-12 | 1993-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
JP3854306B2 (en) | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Humanized and chimeric monoclonal antibodies |
DE69233750D1 (en) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Libraries of heterodimeric receptors using phagemids |
US5374617A (en) | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
FR2676058B1 (en) | 1991-04-30 | 1994-02-25 | Hoechst Lab | GLYCOSYLATED PRODUCTS, THEIR PREPARATION PROCESS AND THEIR USE IN THE TREATMENT OF CANCERS. |
CA2090876A1 (en) | 1991-07-03 | 1993-01-04 | Satoru Nakai | Apoptosis regulating composition |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
DK0605522T3 (en) | 1991-09-23 | 2000-01-17 | Medical Res Council | Process for producing humanized antibodies |
DE69229254T2 (en) | 1991-10-30 | 1999-09-23 | Idemitsu Kosan Co | Processes for the production of human lymphocytes and human antibodies; and antibodies so produced |
JPH07501451A (en) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
DK1024191T3 (en) | 1991-12-02 | 2008-12-08 | Medical Res Council | Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries |
GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
GB9200417D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
ATE171472T1 (en) | 1992-02-19 | 1998-10-15 | Schering Corp | CLONING AND EXPRESSION OF HUMANIZED MONOCLONAL ANTIBODIES TO HUMAN INTERLEUKIN-4 |
US6036955A (en) | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
US5411860A (en) | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
US5430062A (en) | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
GB9314960D0 (en) | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
JPH08500590A (en) | 1992-08-19 | 1996-01-23 | メレルダウファ−マス−ティカルズ インコーポレイテッド | Anti-angiogenic oligomers |
US5464833A (en) | 1992-08-19 | 1995-11-07 | Otsuka Pharmaceutical Co., Ltd. | Apoptosis regulating composition |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
ES2162823T5 (en) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | IMMUNOGLOBULINS DESPROVISTAS OF LIGHT CHAINS. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1994007515A1 (en) | 1992-10-06 | 1994-04-14 | The Scripps Research Institute | Mutant tissue factor lacking factor vii activation activity |
EP1757694A3 (en) | 1992-11-05 | 2008-02-27 | Sloan Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5399586A (en) | 1993-03-11 | 1995-03-21 | Allergan, Inc. | Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity |
NO941135L (en) | 1993-04-01 | 1994-10-03 | Daiichi Seiyaku Co | Thiazole pyrimidine derivatives |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
WO1994028017A1 (en) | 1993-06-01 | 1994-12-08 | The Scripps Research Institute | Human mutant tissue factor compositions useful as tissue factor antagonists |
US5512269A (en) | 1993-06-09 | 1996-04-30 | Burroughs Wellcome, Co. | Method of treating retained pulmonary secretions |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
GB9315494D0 (en) | 1993-07-27 | 1993-09-08 | Springer Caroline | Improvements relating to prodrugs |
US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
US5935818A (en) | 1995-02-24 | 1999-08-10 | Sloan-Kettering Institute For Cancer Research | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof |
US5539094A (en) | 1993-11-12 | 1996-07-23 | La Jolla Cancer Research Foundation | DNA encoding Bcl-2-associated proteins |
GB9323429D0 (en) | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
US5622829A (en) | 1993-12-08 | 1997-04-22 | The Regents Of The University Of California | Genetic markers for breast, ovarian, and prostatic cancer |
GB9326136D0 (en) | 1993-12-22 | 1994-02-23 | Erba Carlo Spa | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
US5565491A (en) | 1994-01-31 | 1996-10-15 | Bristol-Myers Squibb Company | Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation |
US5583034A (en) | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5591717A (en) | 1994-04-06 | 1997-01-07 | Rojko; Jennifer L. | Branched apogenic peptide for inducing apoptosis |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
US5618925A (en) | 1994-04-28 | 1997-04-08 | Les Laboratories Aeterna Inc. | Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof |
DE4417865A1 (en) | 1994-05-20 | 1995-11-23 | Behringwerke Ag | Two component tumour therapy using necrosis inducing agent |
US5605826A (en) | 1994-06-10 | 1997-02-25 | Panorama Research, Inc. | 24 kilodalton cytoplasmic protease activating DNA fragmentation in apoptosis |
HU220347B (en) | 1994-07-11 | 2001-12-28 | Board Of Regents The University Of Texas System | Composition for the specific coagulation of vasculature |
GB9415167D0 (en) | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
US5709999A (en) | 1994-08-12 | 1998-01-20 | Myriad Genetics Inc. | Linked breast and ovarian cancer susceptibility gene |
US5693473A (en) | 1994-08-12 | 1997-12-02 | Myriad Genetics, Inc. | Linked breast and ovarian cancer susceptibility gene |
US5747282A (en) | 1994-08-12 | 1998-05-05 | Myraid Genetics, Inc. | 17Q-linked breast and ovarian cancer susceptibility gene |
US5753441A (en) | 1994-08-12 | 1998-05-19 | Myriad Genetics, Inc. | 170-linked breast and ovarian cancer susceptibility gene |
US5710001A (en) | 1994-08-12 | 1998-01-20 | Myriad Genetics, Inc. | 17q-linked breast and ovarian cancer susceptibility gene |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US5776743A (en) | 1994-09-06 | 1998-07-07 | La Jolla Cancer Research Foundation | Method of sensitizing tumor cells with adenovirus E1A |
JP2783315B2 (en) * | 1994-09-19 | 1998-08-06 | 日本製紙株式会社 | Antiretroviral agent |
US5561122A (en) | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
GB9426133D0 (en) | 1994-12-23 | 1995-02-22 | Zeneca Ltd | Chemical compounds |
US5696092A (en) | 1995-03-07 | 1997-12-09 | George Washington University | Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers |
US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US5571523A (en) | 1995-03-09 | 1996-11-05 | President And Fellows Of Harvard College | Antioxidant-induced apoptosis in vascular smooth muscle cells |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
GB9510830D0 (en) | 1995-05-27 | 1995-07-19 | Zeneca Ltd | Proteins |
US5750653A (en) | 1995-06-07 | 1998-05-12 | The Regents Of The University Of California | Protein, FAF1, which potentiates Fas-mediated apoptosis and uses thereof |
US5646298A (en) | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
EP0751144B1 (en) | 1995-06-27 | 2004-10-06 | Pharmachemie B.V. | Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy |
US5763223A (en) | 1995-06-29 | 1998-06-09 | Immunex Corporation | DNA encoding a cytokine that induces apoptosis |
GB9517001D0 (en) | 1995-08-18 | 1995-10-18 | Denny William | Enediyne compounds |
GB9516943D0 (en) | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
JP2830788B2 (en) | 1995-08-25 | 1998-12-02 | トヨタ自動車株式会社 | Intake cooling structure in engine room |
US5756294A (en) | 1995-09-25 | 1998-05-26 | Oncormed, Inc. | Susceptibility mutation for breast and ovarian cancer |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
JP2000502698A (en) | 1995-12-29 | 2000-03-07 | エンザクタ アール アンド ディ リミテッド | Cytotoxic reagent |
GB9601640D0 (en) | 1996-01-26 | 1996-03-27 | Cancer Res Campaign Tech | Ligand directed enzyme prodrug therapy |
US5654155A (en) | 1996-02-12 | 1997-08-05 | Oncormed, Inc. | Consensus sequence of the human BRCA1 gene |
US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
US6750044B1 (en) | 1996-10-17 | 2004-06-15 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids |
CA2278106C (en) | 1997-01-22 | 2005-04-12 | Board Of Regents, The University Of Texas System | Tissue factor methods and compositions for coagulation and tumor treatment |
EP0973804B1 (en) | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
US6300308B1 (en) * | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
US6028061A (en) | 1998-06-18 | 2000-02-22 | Children's Medical Center Corp | Angiogenesis inhibitors and use thereof |
US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
EP1096955B9 (en) * | 1998-07-13 | 2006-07-05 | Board of Regents, The University of Texas System | Uses of antibodies to aminophospholipids for cancer treatment |
US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
CA2331789C (en) | 1998-07-13 | 2013-09-10 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
NZ514558A (en) * | 1999-03-31 | 2004-02-27 | Uaf Technologies And Res Llc | Viral treatment |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
AU6208100A (en) * | 1999-07-12 | 2001-01-30 | Board Of Regents, The University Of Texas System | Cancer treatment using angiopoietins targeted to aminophospholipids |
WO2001066785A1 (en) * | 2000-03-08 | 2001-09-13 | National Jewish Medical And Research Center | Phosphatidyl serine receptors and uses thereof |
AU2001245647A1 (en) * | 2000-03-14 | 2001-09-24 | Idec Pharmaceuticals Corporation | Antibodies that bind phosphatidyl serine and a method of their use |
US20030124132A1 (en) | 2001-09-27 | 2003-07-03 | Board Of Regents, The University Of Texas System | Combined compositions for tumor vasculature coaguligand treatment |
EP1476752A4 (en) * | 2002-02-27 | 2008-02-13 | Bio Merieux Inc | Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome |
US7714109B2 (en) * | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
US7906115B2 (en) * | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7455833B2 (en) * | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
US7678386B2 (en) * | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
US7622118B2 (en) * | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
US7611704B2 (en) * | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
BR0312692A (en) * | 2002-07-15 | 2007-06-26 | Univ Texas | selected antibodies and duramycin peptides that bind to anionic phospholipids and aminophospholipids and their uses in the treatment of viral infections and cancer |
US7615223B2 (en) * | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
US20040131622A1 (en) * | 2002-07-15 | 2004-07-08 | Board Of Regents | Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids |
US7625563B2 (en) * | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
US7790159B2 (en) * | 2002-07-15 | 2010-09-07 | Board Of Regents, The University Of Texas System | Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids |
US7247303B2 (en) * | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
-
2003
- 2003-07-15 BR BRPI0312692-7A patent/BR0312692A/en not_active Application Discontinuation
- 2003-07-15 DK DK10184072.6T patent/DK2269656T3/en active
- 2003-07-15 KR KR1020127028027A patent/KR101690826B1/en active IP Right Grant
- 2003-07-15 KR KR1020127027916A patent/KR101669709B1/en active IP Right Grant
- 2003-07-15 CA CA2491310A patent/CA2491310C/en not_active Expired - Fee Related
- 2003-07-15 NZ NZ537690A patent/NZ537690A/en not_active IP Right Cessation
- 2003-07-15 KR KR1020117004673A patent/KR101257584B1/en active IP Right Grant
- 2003-07-15 EP EP10184756A patent/EP2263697A3/en not_active Withdrawn
- 2003-07-15 SI SI200332393T patent/SI2269656T1/en unknown
- 2003-07-15 EP EP10184072.6A patent/EP2269656B1/en not_active Expired - Lifetime
- 2003-07-15 WO PCT/US2003/021925 patent/WO2004006847A2/en active Application Filing
- 2003-07-15 DE DE60335383T patent/DE60335383D1/en not_active Expired - Lifetime
- 2003-07-15 KR KR1020057000602A patent/KR101073306B1/en not_active IP Right Cessation
- 2003-07-15 MX MXPA05000652A patent/MXPA05000652A/en active IP Right Grant
- 2003-07-15 CN CN200910142300.2A patent/CN101653603B/en not_active Expired - Fee Related
- 2003-07-15 DK DK03764600.7T patent/DK1537146T3/en active
- 2003-07-15 ES ES03764600T patent/ES2358730T3/en not_active Expired - Lifetime
- 2003-07-15 EP EP20100184146 patent/EP2357009A1/en not_active Ceased
- 2003-07-15 CN CN201210153295.7A patent/CN104225610B/en not_active Expired - Fee Related
- 2003-07-15 CA CA2894009A patent/CA2894009C/en not_active Expired - Lifetime
- 2003-07-15 MX MX2011000908A patent/MX337052B/en unknown
- 2003-07-15 EP EP10184821A patent/EP2266624B1/en not_active Expired - Lifetime
- 2003-07-15 KR KR1020117004674A patent/KR20110027849A/en active Application Filing
- 2003-07-15 NZ NZ611387A patent/NZ611387A/en not_active IP Right Cessation
- 2003-07-15 EP EP03764600A patent/EP1537146B9/en not_active Expired - Lifetime
- 2003-07-15 ES ES10184072.6T patent/ES2524325T3/en not_active Expired - Lifetime
- 2003-07-15 JP JP2004521771A patent/JP4827411B2/en not_active Expired - Fee Related
- 2003-07-15 CN CNB038167514A patent/CN100506846C/en not_active Expired - Fee Related
- 2003-07-15 DK DK10184862.0T patent/DK2283868T3/en active
- 2003-07-15 US US10/620,850 patent/US20040175378A1/en not_active Abandoned
- 2003-07-15 KR KR1020117030898A patent/KR20120068769A/en not_active Application Discontinuation
- 2003-07-15 KR KR1020117004675A patent/KR20110025885A/en active Application Filing
- 2003-07-15 EP EP10184896A patent/EP2281578A3/en not_active Withdrawn
- 2003-07-15 PT PT03764600T patent/PT1537146E/en unknown
- 2003-07-15 NZ NZ574146A patent/NZ574146A/en not_active IP Right Cessation
- 2003-07-15 EP EP10184862.0A patent/EP2283868B1/en not_active Expired - Lifetime
- 2003-07-15 NZ NZ596825A patent/NZ596825A/en not_active IP Right Cessation
- 2003-07-15 AT AT03764600T patent/ATE491725T1/en active
- 2003-07-15 AU AU2003247869A patent/AU2003247869C1/en not_active Ceased
- 2003-07-15 PT PT101840726T patent/PT2269656E/en unknown
- 2003-07-15 IL IL16526703A patent/IL165267A0/en unknown
- 2003-07-15 NZ NZ584715A patent/NZ584715A/en not_active IP Right Cessation
- 2003-07-15 EP EP10184927A patent/EP2283869A3/en not_active Withdrawn
- 2003-07-15 US US10/621,269 patent/US7572442B2/en active Active
- 2003-07-15 KR KR1020147026484A patent/KR20150021911A/en not_active Application Discontinuation
- 2003-07-15 CN CN201210153265.6A patent/CN104130327A/en active Pending
- 2003-07-15 CN CN201210153318.4A patent/CN104001181B/en not_active Expired - Fee Related
-
2004
- 2004-11-17 IL IL165267A patent/IL165267A/en active IP Right Grant
-
2005
- 2005-01-13 ZA ZA200500363A patent/ZA200500363B/en unknown
- 2005-08-25 HK HK05107478.1A patent/HK1075256A1/en not_active IP Right Cessation
-
2008
- 2008-11-17 IL IL195328A patent/IL195328A/en active IP Right Grant
-
2009
- 2009-10-01 AU AU2009222538A patent/AU2009222538B2/en not_active Ceased
-
2010
- 2010-08-18 JP JP2010183517A patent/JP5408799B2/en not_active Expired - Fee Related
-
2011
- 2011-06-28 HK HK11106666.7A patent/HK1152491A1/en not_active IP Right Cessation
- 2011-07-26 JP JP2011163732A patent/JP2011213737A/en not_active Withdrawn
-
2012
- 2012-12-26 IL IL223907A patent/IL223907A/en active IP Right Grant
- 2012-12-26 IL IL223908A patent/IL223908A/en active IP Right Grant
-
2013
- 2013-08-08 JP JP2013165247A patent/JP5781571B2/en not_active Expired - Fee Related
-
2015
- 2015-01-30 HK HK15101051.7A patent/HK1200360A1/en not_active IP Right Cessation
- 2015-02-26 JP JP2015036157A patent/JP2015134791A/en not_active Withdrawn
- 2015-03-25 HK HK15103048.9A patent/HK1202561A1/en unknown
- 2015-03-26 HK HK15103089.9A patent/HK1202437A1/en not_active IP Right Cessation
-
2016
- 2016-04-28 JP JP2016090246A patent/JP6188258B2/en not_active Expired - Fee Related
- 2016-06-03 JP JP2016111546A patent/JP2016164197A/en not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2491310A1 (en) | Compositions comprising cell-impermeant duramycin derivatives | |
US10758556B2 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
US6399068B1 (en) | Method of treatment with a non-antigenic toxin-conjugate and fusion protein of internalizing receptor system | |
AU2005220212B2 (en) | Immunotherapy of autoimmune disorders using antibodies which target B-cells | |
US5958412A (en) | Methods of treating colon cancer utilizing tumor-specific antibodies | |
US7544487B2 (en) | Fusion proteins containing recombinant cytotoxic RNAses | |
Reff et al. | A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications | |
US6299876B1 (en) | Cytotoxic drug therapy | |
TW201736400A (en) | Antigen binding proteins that bind PD-L1 | |
IE76715B1 (en) | Bispecific and oligospecific mono- and oligolvalent receptors the preparation and use thereof | |
EP3865151A1 (en) | Method for manufacturing antibody-drug conjugate | |
CA2444661A1 (en) | Use of cd23 antagonists for the treatment of neoplastic disorders | |
KR20190129056A (en) | Pharmaceutical combinations comprising anti-LY75 antibodies | |
EA007467B1 (en) | Use of cd23 antagonists for the treatment of neoplastic disorders | |
DE60129741T2 (en) | TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER AND INFECTION DISEASES | |
CA2389386A1 (en) | Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents | |
CA3114922A1 (en) | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy | |
CN112236143A (en) | Pharmaceutical combination | |
Newton et al. | Anti-tumor ribonuclease, combined with or conjugated to monoclonal antibody MRK16, overcomes multidrug resistance to vincristine in vitro and in vivo | |
US20240091372A1 (en) | Anti-doppel antibody drug conjugates | |
WO2024067764A1 (en) | Anti-gpc3 monoclonal antibody/bispecific antibody or antigen-binding fragment thereof and use thereof | |
Tsousi | Bispecific Antibody-Drug Conjugates | |
WO2019152827A1 (en) | Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof | |
Class et al. | Patent application title: Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides Inventors: Philip E. Thorpe (Dallas, TX, US) Philip E. Thorpe (Dallas, TX, US) Jin He (Catonsville, MD, US) Assignees: Board of Regents, The University of Texas System | |
Ng et al. | Antibody Fusion Proteins: Applications in Brain Targeting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190715 |